OHSU Rare Disease Research Consortium Symposium 2015: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
Line 18: | Line 18: | ||
|-- | |-- | ||
| 4:00-5:00 | | 4:00-5:00 | ||
| [http://www.kathiresanlab.org/about-sek/ Sekar Kathiresan, M.D.] | | [http://www.kathiresanlab.org/about-sek/ Sekar Kathiresan, M.D.], Director of preventive cardiology, Mass General Hospital | ||
| Leveraging human knockouts to understand risk for and protection from disease | | Leveraging human knockouts to understand risk for and protection from disease | ||
|-- | |-- | ||
Line 34: | Line 34: | ||
|-- | |-- | ||
| 6:30 to 6:35 | | 6:30 to 6:35 | ||
| [https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D.,MBA] | | [https://www.linkedin.com/in/hoatlin Maureen Hoatlin, Ph.D.,MBA], co-chair OHSU Rare Disease Research Consortium | ||
| OHSU Rare Disease Consortium overview and objective of the symposium | | OHSU Rare Disease Consortium overview and objective of the symposium | ||
Line 65: | Line 65: | ||
|-- | |-- | ||
| 7:40 to 8:20 | | 7:40 to 8:20 | ||
| Xiaobing Quan, M.D., Ph.D | | Xiaobing Quan, M.D., Ph.D, Executive Director, Translational Medicine at Regeneron Pharmaceuticals, Inc. | ||
| Accelerating opportunities from discovery to clinic in rare disease research | | Accelerating opportunities from discovery to clinic in rare disease research | ||
|-- | |-- |
Revision as of 21:26, 30 March 2015
April 7, 2015, from 4-8:30 pm at OHSU in the Joseph Vey Conference Center
General InfoSchedule
|